Enhanced blood glucose-lowering effect & increased susceptibility to hypoglycemia w/ oral antidiabetic medicinal products, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates & sulphonamide antibiotics. Reduced blood glucose-lowering effect w/ corticosteroids, danazol, diazoxide, diuretics, glucagon, INH, estrogens & progestogens (eg, OCs), phenothiazine derivatives, somatropin, sympathomimetic drugs (eg, epinephrine, salbutamol, terbutaline), thyroid hormones, PIs & atypical antipsychotic medicinal products (eg, olanzapine & clozapine). May potentiate or weaken blood glucose-lowering effect w/ β-blockers, clonidine, lithium salts or alcohol. May cause hypoglycemia w/ pentamidine. Signs of adrenergic counter-regulation may be reduced or absent w/ sympatholytic medicinal products eg, β-blockers, clonidine, guanethidine & reserpine. Biosulidd N
Increased insulin requirements w/ glucocorticoids, thyroid hormones, growth hormone, danazol, β2
-sympatomimetics (eg, ritodrine, salbutamol, terbutaline), thiazides. Reduced insulin requirements w/ oral hypoglycemic agents, salicylates (eg, acetylsalicylic acid), MAOIs, ACE inhibitors (captopril, enalapril), angiotensin II receptor blockers, non-selective β-blocking agents & alcohol. Somatostatin analogues (octreotide, lanreotide) may both decrease or increase insulin dose requirements.